[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lung-cancer-small-cell\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lung-cancer-small-cell":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,74,95,121],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100609797","engagement-of-veterans-with-lung-cancer-100609797",false,"NCT07219251","Engagement of Veterans With Lung Cancer","Engagement of Veterans With Lung Cancer (EVLC)","EVLC","Inclusion Criteria:\n\n1. Veteran patients with diagnosis of any stage of lung cancer;\n2. 18 years of age or older;\n3. English- or Spanish-speaking;\n4. can self-administer questionnaires in English or Spanish;\n5. valid telephone number;\n6. receiving oncology care at participating sites;\n7. currently newly diagnosed or receiving or having completed systemic anti-cancer therapy and\u002For radiation therapy within 12 months, defined as oral, injection, or intravenous therapy (chemotherapy, targeted therapy, or immunotherapy)\n\nExclusion Criteria:\n\n1. no capacity to consent;\n2. actively receiving hospice care","ALL","18 Years",{"count":20,"type":21},194,"ESTIMATED","INTERVENTIONAL",[24],"NA","This research study will help our understanding of whether additional support for Veterans with lung cancer can improve their quality of life.",[27,28,29,30,31,32],"Lung Cancer (NSCLC)","Lung Adenocarcinoma","Lung Cancer, Non-Small Cell","Lung Carcinoma","Lung Cancer, Small Cell","Lung Adenocarcinoma With Bronchiolo-alveolar Feature",[34,35],"lung","cancer","RECRUITING","2026-03-02",{"date":39,"type":40},"2026-03-03","ACTUAL",{"date":42,"type":40},"2026-02-27",{"date":44,"type":21},"2032-12-31",{"name":46,"class":47},"Palo Alto Veterans Institute for Research","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100586336","phase-2-hypofractionated-radiotherapy-followed-by-chemo-immunotherapy-induction-therapy-100586336","NCT06914050","Hypofractionated Radiotherapy Followed by Chemo-immunotherapy Induction Therapy","An Exploratory Study on the Treatment of Limited-stage Small Cell Lung Cancer With Induction Therapy of Adebrelimab Combined With Chemotherapy Followed by Thoracic Radiotherapy After Hypofractionated Radiotherapy","Inclusion Criteria:\n\n1\\. Age 18-70 years old; 2. Limited-stage small cell lung cancer (AJCC 8th) confirmed by histology or cytology; 3. Subjects have not received any treatment for SCLC; 4. Have measurable target lesions according to RECIST v1.1; 5. ECOG score of 0-1; 6. Life expectancy ≥ 12 weeks; 7. Normal function of major organs, that is, meet the following criteria:\n\n1. Routine blood tests must meet the following criteria (no blood transfusion, no use of hematopoietic factors, and no use of drug correction within 14 days):\n\n   1. ANC ≥ 1.5×109\u002FL;\n   2. PLT ≥ 100×109\u002FL;\n   3. HB ≥ 90 g\u002FL;\n2. Biochemical tests must meet the following criteria:\n\n   1. TBIL ≤ 1.5×ULN;\n   2. ALT, AST≤ 2.5×ULN;\n   3. Serum creatinine sCr≤1.5×ULN, endogenous creatinine clearance ≥50mL\u002Fmin (Cockcroft-Gault formula);\n3. Coagulation function must meet the following requirements: INR≤1.5×ULN and APTT≤1.5×ULN; 8. Female subjects of childbearing age must undergo a serum pregnancy test within 3 days before starting the study medication, and the result must be negative, and they must be willing to use a medically approved high-efficiency contraceptive measure (such as intrauterine contraceptive device, contraceptive pills or condoms) during the study and within 3 months after the last administration of the study medication; for male subjects whose partners are female subjects of childbearing age, they must be surgically sterilized or agree to use an effective contraceptive method during the study and within 3 months after the last administration of the study medication.\n\n9\\. The subjects voluntarily join this study, sign the informed consent form, have good compliance, and cooperate with follow-up visits.\n\nExclusion Criteria:\n\n1. Central nervous system metastasis;\n2. Any active autoimmune disease or history of autoimmune disease (including, but not limited to: moderate interstitial pneumonia and above, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, myocarditis, nephritis; patients with vitiligo or childhood asthma that has completely resolved and does not require any intervention as an adult can be included; patients who require bronchodilators for medical intervention are not included;\n3. Patients with congenital or acquired immune deficiency, such as human immunodeficiency virus (HIV) infection, active hepatitis B (HBV DNA ≥ 500 IU\u002FmL), hepatitis C (positive hepatitis C antibody, and HCV-RNA is higher than the detection limit of the analytical method) or co-infection with hepatitis B and hepatitis C, active pulmonary tuberculosis;\n4. Immunosuppressive drugs have been used within 14 days before the first use of study drugs, excluding nasal spray and inhaled corticosteroids or physiological doses of systemic steroid hormones (i.e. no more than 10 mg\u002Fday prednisone or its equivalent);\n5. Vaccination with live attenuated vaccine within 4 weeks before the first dose or planned during the study;\n6. Suffering from other malignant tumors in the past 3 years;\n7. Evidence of past or current pulmonary fibrosis, interstitial pneumonia (grade II or above), pneumoconiosis, radiological pneumonia, drug-induced pneumonia, and severe lung function impairment;\n8. Uncontrolled hypertension;\n9. Suffering from myocardial ischemia or myocardial infarction above grade II, poorly controlled arrhythmias (including QTc interval ≥450ms for males and ≥470ms for females). According to NYHA standards, patients with grade III-IV heart failure, or left ventricular ejection fraction (LVEF) \\\u003C50% indicated by cardiac ultrasound examination, had myocardial infarction within 6 months before enrollment, New York Heart Association grade II or above heart failure, uncontrolled angina pectoris, uncontrolled severe ventricular arrhythmias, clinically significant pericardial disease, or ECG indicating acute ischemia or abnormal active conduction system;\n10. Severe infection within 4 weeks before the first medication (such as: intravenous infusion of antibiotics, antifungal or antiviral drugs for more than 7 days), or unexplained fever \\>38.5°C during the screening period\u002Fbefore the first medication;\n\n1 1. Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation; 12. Pregnant or lactating women; patients with fertility who are unwilling or unable to take effective contraceptive measures; 13. Known to have allergic reactions, hypersensitivity reactions or intolerance to adebrelimab (SHR-1316), etoposide, cisplatin or its excipients; 14. Subjects who are participating in other clinical studies or whose first medication time is less than 4 weeks from the end of the previous clinical study (last medication) or 5 half-lives of the study drug; 15. Subjects with a history of psychotropic drug abuse, alcoholism or drug abuse; 16. The researcher believes that there are any conditions that may harm the subject or cause the subject to be unable to meet or perform the study requirements.","70 Years",{"count":58,"type":21},30,[60],"PHASE2","Radiotherapy can activate local and systemic immune responses through a variety of mechanisms, which can enhance anti-tumor immune effects. The dose fractionation pattern of radiotherapy has an important influence on the occurrence of immune-induced effects. Stereotactic body radiation therapy (SBRT) has obvious advantages in activating interferon effects and inducing abscopal effects. SBRT combined with immunity can enhance the abscopal effect induced by radiotherapy and play a synergistic role. The 8Gy×3 fractionation scheme is currently the most widely used stereotactic radiotherapy scheme. Because we conducted this study, the primary lesion received large-fraction partial tumor irradiation and then received adebrelimab combined with chemotherapy induction treatment for 2 cycles, followed by sequential chest radiotherapy for the treatment of limited-stage small cell lung cancer, to explore the effectiveness and safety.",[31,63],"Limited-stage Small Cell Lung Cancer (LS-SCLC)","NOT_YET_RECRUITING","2025-04-23",{"date":67,"type":40},"2025-04-25",{"date":69,"type":21},"2025-04",{"date":71,"type":21},"2028-04",{"name":73,"class":47},"Tianjin Medical University Cancer Institute and Hospital",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":48},"100576095","a-study-on-the-efficacy-of-atezolizumab-combined-with-chemotherapy-100576095","NCT06780826","A Study on the Efficacy of Atezolizumab Combined with Chemotherapy","A Simulated RCT Study on the Efficacy of Atezolizumab Combined with Chemotherapy Versus Placebo Combined with Chemotherapy in Small Cell Lung Cancer","Inclusion Criteria:\n\n* Signed Informed Consent Form\n* Male or female, 18 years of age or older\n* ECOG performance status of 0 or 1\n* Histologically or cytologically confirmed ES-SCLC (per the Veterans Administration Lung Study Group (VALG) staging system\n* No prior treatment for ES-SCLC\n* Patients with a history of treated asymptomatic CNS metastases are eligible, provided they meet all of the following criteria:\n\n  1. Only supratentorial and cerebellar metastases allowed (i.e., no metastases\n  2. to midbrain, pons, medulla or spinal cord)\n  3. No ongoing requirement for corticosteroids as therapy for CNS disease\n  4. No stereotactic radiation within 7 days\n  5. No evidence of interim progression between the completion of CNS- directed therapy and the screening radiographic study.\n  6. Patients with new asymptomatic CNS metastases detected at the screening scan must receive radiation therapy and\u002For surgery for CNS metastases. Following treatment, these patients may then be eligible without the need for an additional brain scan prior to randomization, if all other criteria are met.\n* Measurable disease, as defined by RECIST v1.1 Previously irradiated lesions can only be considered as measurable disease if disease progression has been unequivocally documented at that site since radiation and the previously irradiated lesion is not the only site of disease.\n* Adequate hematologic and end organ function, defined by the following laboratory results obtained within 14 days prior to randomization:\n\nANC ≥ 1500 cells\u002FμL without granulocyte colony-stimulating factor support; Lymphocyte count ≥ 500\u002FμL; Platelet count ≥ 100,000\u002FμL without transfusion; Hemoglobin ≥ 9.0 g\u002FdL; Patients may be transfused to meet this criterion. INR or aPTT ≤ 1.5 × upper limit of normal (ULN) This applies only to patients who are not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose. AST, ALT, and alkaline phosphatase ≤ 2.5 × ULN, with the following exceptions: Patients with documented liver metastases: AST and\u002For ALT ≤ 5 × ULN Patients with documented liver or bone metastases: alkaline phosphatase\n\n* 5 × ULN. Serum bilirubin ≤ 1.25 × ULN Patients with known Gilbert disease who have serum bilirubin level ≤ 3 × ULN may be enrolled. Serum creatinine ≤ 1.5 × ULN\n\n  * Patients must submit a pre-treatment tumor tissue sample during the study. Any available tumor tissue sample can be submitted. The tissue sample may be submitted after enrollment.\n  * For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of \\\u003C 1% per year during the treatment period and for at least 90 days after the last dose of study treatment.\n\nExclusion Criteria:\n\n* Active or untreated CNS metastases as determined by computed tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening and prior radiographic assessments\n* Spinal cord compression not definitively treated with surgery and\u002For radiation or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for ≥ 1 week prior to randomization\n* Leptomeningeal disease\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently) Patients with indwelling catheters (e.g., PleurX®) are allowed.\n* Uncontrolled or symptomatic hypercalcemia (\\> 1.5 mmol\u002FL ionized calcium or calcium \\> 12 mg\u002FdL or corrected serum calcium \\> ULN) Patients who are receiving denosumab prior to randomization must be willing and eligible to discontinue its use and replace it with a bisphosphonate while in the study.\n* Malignancies other than SCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death (e.g., expected 5-year OS \\> 90%) treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous-cell skin cancer, localized prostate cancer treated surgically with curative intent, ductal carcinoma in situ treated surgically with curative intent)\n* Women who are pregnant, lactating, or intending to become pregnant during the study\n* History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins\n* Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation\n* History of autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone may be eligible for this study. Patients with controlled Type I diabetes mellitus on a stable dose of insulin regimen are eligible for this study. Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions: Rash must cover less than 10% of body surface area Disease is well controlled at baseline and only requires low potency topical steroids No acute exacerbations of underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation \\[PUVA\\], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, high potency, or oral steroids)\n* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan History of radiation pneumonitis in the radiation field (fibrosis) is permitted.\n* Positive test for HIV\n* Patients with active hepatitis B (chronic or acute; defined as having a positive hepatitis B surface antigen \\[HBsAg\\] test at screening) or hepatitis C Patients with past hepatitis B virus (HBV) infection or resolved HBV infection (defined as the presence of hepatitis B core antibody \\[HBcAb\\] and absence of HBsAg) are eligible. HBV DNA must be obtained in these patients prior to randomization. Patients positive for hepatitis C virus (HCV) antibody are eligible only if PCR is negative for HCV RNA.\n* Active tuberculosis\n* Severe infections at the time of enrollment, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia\n* Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction within 3 months prior to randomization, unstable arrhythmias, or unstable angina Patients with known coronary artery disease, congestive heart failure not meeting the above criteria, or left ventricular ejection fraction \\\u003C 50% must be on a stable medical regimen that is optimized in the opinion of the treating physician, in consultation with a cardiologist if appropriate.\n* Major surgical procedure other than for diagnosis within 28 days prior to randomization or anticipation of need for a major surgical procedure during the course of the study\n* Prior allogeneic bone marrow transplantation or solid organ transplant\n* Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk for treatment complications\n* Previous anti-cancer therapy for ES-SCLC\n* Treatment with any other investigational agent or participation in another clinical study with therapeutic intent within 28 days prior to randomization\n* Administration of a live, attenuated vaccine within 4 weeks before randomization or anticipation that such a live attenuated vaccine will be required during the study",{"count":82,"type":21},1430,"OBSERVATIONAL","This is a multicenter phase III simulated RCT study aimed to compare the efficacy and safety of atezolizumab combined with chemotherapy versus placebo combined with chemotherapy in small cell lung cancer.",[31],"2025-01-13",{"date":88,"type":40},"2025-01-17",{"date":90,"type":40},"2024-08-28",{"date":92,"type":21},"2025-09-30",{"name":94,"class":47},"Shanghai Pulmonary Hospital, Shanghai, China",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":101,"enrollmentInfo":102,"targetDuration":4,"studyType":22,"phases":104,"briefSummary":105,"conditions":106,"keywords":107,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":48},"100572911","the-diagnostic-value-of-bronchoscopic-needle-based-confocal-laser-endomicroscopy-ncle-as-a-real-time-detection-tool-for-diagnosing-peripheral-lung-cancer-a-multi-centre-randomised-controlled-trial-100572911","NCT06739421","The Diagnostic Value of Bronchoscopic Needle-based Confocal Laser Endomicroscopy (nCLE) As a Real-time Detection Tool for Diagnosing Peripheral Lung Cancer: a Multi-centre Randomised Controlled Trial","Inclusion Criteria:\n\n* patients with peripheral lung nodules suspected of lung cancer based on CT scan (10mm≤size\\\u003C30mm);\n* patients requiring diagnostic bronchoscopy procedure to determine the benign or malignant nature of the lung nodule;\n* Patients who can understand the purpose of the trial, participate voluntarily and sign an informed consent form.\n\nExclusion Criteria:\n\n* Inability or non-willingness to provide informed consent;\n* Endobronchial visible malignancy on bronchoscopic inspection;\n* Target lesion within reach of the linear EBUS scope;\n* Failure to comply with the study protocol;\n* Known allergy or risk factors for an allergic reaction to fluorescein;\n* Pregnancy or breast feeding;\n* Haemodynamic instability;\n* Refractory hypoxaemia;\n* Therapeutic anticoagulant use that cannot be withheld for an appropriate interval before the procedure;\n* Unable to tolerate general anaesthesia according to the anaesthesiologist;\n* Undergoing chemotherapy as several chemotherapies have fluorescent properties at the same wavelength (eg, doxorubicin).","90 Years",{"count":103,"type":21},1040,[24],"The goal of this prospective, multi-centre, randomised controlled clinical study is to evaluate the diagnostic efficacy and safety of nCLE guided lung biopsy in patients with for peripheral lung nodules under the assistance of navigation bronchoscopy (NB) and radial endobronchial ultrasound (rEBUS), and assess whether the biopsy techniques, namely transbronchial crybiopsy (TBCB) and transbronchial forceps biopsy (TBFB), would influence the diagnostic efficacy and safety of nCLE guided biopsy.\n\nParticipants will divided into nCLE-NB-rEBUS-forcep biopsy group, nCLE-NB-rEBUS-TBCB group, NB-rEBUS-forcep biopsy group, and NB-rEBUS-TBCB group at a 1:1:1:1 ratio by using central, computerized random sequence, and then undertake nCLE-NB-rEBUS-forcep biopsy, nCLE-NB-rEBUS-TBCB, NB-rEBUS-forcep biopsy, and NB-rEBUS-TBCB according to the group.\n\nResearchers will compare the diagnostic yield and incidence of adverse events of the four biopsy techniques.",[29,31],[108,109,110,111],"needle-based confocal laser endomicroscopy","peripheral lung cancer","peripheral lung nodules","lung biopsy","2024-12-17",{"date":114,"type":40},"2024-12-18",{"date":116,"type":21},"2025-01-01",{"date":118,"type":21},"2026-01-31",{"name":120,"class":47},"China-Japan Friendship Hospital",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":22,"phases":130,"briefSummary":131,"conditions":132,"keywords":133,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":48},"100569801","phase-2-efficacy-and-safety-of-first-line-treatment-for-extensive-stage-small-cell-lung-cancer-using-a-combination-therapy-of-trilaciclib-envafolimab-etoposide-and-carboplatin-100569801","NCT06698965","Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin","A Randomized, Controlled Phase II Clinical Study on the Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin","Inclusion Criteria:\n\n* Age ≥ 18 years, regardless of gender;\n* Small cell lung cancer (SCLC) confirmed by histology or cytology;\n* Extensive-stage small cell lung cancer, classified as stage IV (any T, any N, M1a\u002Fb\u002Fc) according to the 8th edition of the AJCC, or T3-4 due to multiple pulmonary nodules or tumor\u002Fnodule volume too large to be included in a tolerable radiotherapy plan;\n* At least one measurable lesion on imaging（RECIST 1.1）;\n* Have not received any systemic anti-tumor treatment for extensive-stage diseases in the past. For patients who have received adjuvant\u002Fneoadjuvant chemotherapy in the past, or have received curative radiotherapy and chemotherapy for advanced diseases, if there is a gap of at least 6 months between disease progression or recurrence and the end of the last chemotherapy drug treatment, they are eligible to be included in this study;\n* Patients with asymptomatic brain metastases or brain metastases whose symptoms have stabilized after treatment;\n* Subjects are allowed to receive palliative radiation therapy (including cranial radiation therapy for symptomatic brain metastases), but the radiation therapy must be completed at least one week before enrollment;\n* The laboratory test results meet the following criteria: Hemoglobin ≥ 90 g\u002FL, neutrophil count ≥ 1.5 × 10\\^9\u002FL, platelet count ≥ 100 × 10\\^9\u002FL; Creatinine clearance rate (CrCl) ≥ 60 mL\u002Fmin (as calculated using the Cockcroft-Gault formula); Total bilirubin ≤ 1.5 times the upper limit of normal (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN or ≤ 5 × ULN (for patients with liver metastases); albumin ≥ 30 g\u002FL; International normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 times ULN; Thyroid stimulating hormone (TSH) is within the normal range. If the baseline TSH exceeds the normal range, subjects with total T3 (or FT3) and FT4 within the normal range can also be enrolled; The myocardial enzyme profile is within the normal range (simple laboratory abnormalities that are deemed clinically insignificant by the researchers are also allowed to be included).;\n* ECOG PS score 0 or 1;\n* Expected survival time ≥ 3 months;\n* For Female Participants: All Female Participants with potential fertility must have a negative serum pregnancy test result during the screening period, and must take reliable contraceptive measures from signing the informed consent form until 3 months after the last dose;\n* Understand and sign the informed consent form.\n\nExclusion Criteria:\n\n* Diagnosed with malignant diseases other than SCLC within 5 years prior to the first administration (excluding curative basal cell carcinoma, squamous cell carcinoma, and\u002For excised carcinoma in situ);\n* Mixed SCLC and NSCLC confirmed by histology or cytology;\n* Currently participating in interventional clinical research treatment, or having received other investigational drugs or used investigational devices within 4 weeks prior to the first administration;\n* Previously received the following therapies: anti-PD-1, anti-PD-L1, or anti-PD-L2 drugs, or drugs that stimulate or synergistically inhibit T cell receptors (such as CTLA-4, OX-40, CD137);\n* Within 2 weeks before the first administration, the individual has received systematic systemic treatment with traditional Chinese patent medicines and simple preparations with anti lung cancer indications or drugs with immunomodulatory effects (including thymosin, interferon, interleukin, except for local use to control pleural effusion and pleural effusion);\n* Within 2 years prior to the first administration, the individual has been an active autoimmune disease requiring systemic treatment (such as the use of disease relieving drugs, corticosteroids, or immunosuppressants). Alternative therapies (such as thyroid hormone, insulin, or physiological glucocorticoids used for adrenal or pituitary insufficiency) are not considered systemic treatments;\n* Within 7 days prior to the first administration of the study, the individual was receiving systemic corticosteroid therapy (excluding topical corticosteroids via nasal spray, inhalation, or other routes) or any other form of immunosuppressive therapy; Note: Physiological doses of glucocorticoids (≤ 10 mg\u002Fday of prednisone or equivalent) are allowed to be used;\n* Individuals who are known to be allergic to the active ingredients or excipients of the investigational drugs, such as trilaciclib, envafolimab, etoposide, carboplatin, etc;\n* Patients with clinically uncontrollable pleural\u002Fperitoneal effusion (those who do not require drainage or have no significant increase in effusion after stopping drainage for 3 days can be enrolled);\n* Known history of human immunodeficiency virus (HIV) infection (i.e. HIV 1\u002F2 antibody positive) or untreated active HBV, HCV;\n* Pregnant or lactating female participants;\n* Uncontrolled ischemic heart disease or clinically significant congestive heart failure (NYHA class III or IV)",{"count":129,"type":21},52,[60],"This prospective, randomized, controlled phase II study aims to evaluate the efficacy of combination therapy with Envafolimab and chemotherapy in first-line extensive stage SCLC, as well as the impact of Trilaciclib on the incidence of myelosuppression and anti-tumor effects in patients.",[31],[134,135,136,137],"SCLC","first-line treatment","immunotherapy","myelosuppression","2024-11-19",{"date":140,"type":40},"2024-11-21",{"date":142,"type":40},"2024-10-13",{"date":144,"type":21},"2029-10-31",{"name":146,"class":47},"Shanghai Chest Hospital"]